BR112014008744A2 - preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer - Google Patents

preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer

Info

Publication number
BR112014008744A2
BR112014008744A2 BR112014008744A BR112014008744A BR112014008744A2 BR 112014008744 A2 BR112014008744 A2 BR 112014008744A2 BR 112014008744 A BR112014008744 A BR 112014008744A BR 112014008744 A BR112014008744 A BR 112014008744A BR 112014008744 A2 BR112014008744 A2 BR 112014008744A2
Authority
BR
Brazil
Prior art keywords
release preparation
prolonged release
alzheimer
delaying
onset
Prior art date
Application number
BR112014008744A
Other languages
English (en)
Portuguese (pt)
Inventor
Takenaka Kaoru
Ishii Yumiko
Murakawa Yusuke
Tanoue Yutaka
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014008744(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112014008744A2 publication Critical patent/BR112014008744A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112014008744A 2011-10-21 2012-10-19 preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer BR112014008744A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011232302 2011-10-21
PCT/JP2012/077662 WO2013058409A1 (en) 2011-10-21 2012-10-19 Sustained-release preparation

Publications (1)

Publication Number Publication Date
BR112014008744A2 true BR112014008744A2 (pt) 2017-04-18

Family

ID=47178262

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014008744A BR112014008744A2 (pt) 2011-10-21 2012-10-19 preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer

Country Status (30)

Country Link
US (1) US9907789B2 (https=)
EP (1) EP2768487B1 (https=)
JP (1) JP6093762B2 (https=)
KR (1) KR20140081826A (https=)
CN (1) CN104039313A (https=)
AP (1) AP2014007645A0 (https=)
AR (1) AR088398A1 (https=)
AU (1) AU2012326976B2 (https=)
BR (1) BR112014008744A2 (https=)
CA (1) CA2852417A1 (https=)
CL (1) CL2014000992A1 (https=)
CO (1) CO6960544A2 (https=)
CR (1) CR20140213A (https=)
DO (1) DOP2014000077A (https=)
EA (1) EA201490840A1 (https=)
EC (1) ECSP14013328A (https=)
IL (1) IL232114A0 (https=)
IN (1) IN2014DN03169A (https=)
MA (1) MA35717B1 (https=)
MX (1) MX2014004679A (https=)
NZ (1) NZ624275A (https=)
PE (1) PE20141189A1 (https=)
PH (1) PH12014500856A1 (https=)
SG (2) SG2014012025A (https=)
TN (1) TN2014000152A1 (https=)
TW (1) TW201323018A (https=)
UA (1) UA113858C2 (https=)
UY (1) UY34403A (https=)
WO (1) WO2013058409A1 (https=)
ZA (1) ZA201403103B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012326976B2 (en) 2011-10-21 2017-08-17 Takeda Pharmaceutical Company Limited Sustained-release preparation
ES2571479T3 (es) 2012-04-20 2016-05-25 Gilead Sciences Inc Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH
US20150141517A1 (en) * 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
JP2023066053A (ja) * 2021-10-28 2023-05-15 東和薬品株式会社 放出制御医薬組成物
WO2025064867A1 (en) * 2023-09-21 2025-03-27 Yuva Biosciences, Inc. Delivery system for mitochondrial health enhancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
JP3140465B2 (ja) 1992-09-18 2001-03-05 山之内製薬株式会社 ハイドロゲル徐放性製剤
JPH06316517A (ja) 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
WO1998056359A2 (de) 1997-06-13 1998-12-17 Roland Bodmeier Zusammensetzungen, die die wirkstofffreisetzung verzögern
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US20040219208A1 (en) 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20100137023A (ko) 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
IN192749B (https=) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US8980322B2 (en) 2003-03-17 2015-03-17 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
JP2005015477A (ja) 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
TW200510002A (en) 2003-06-06 2005-03-16 Takeda Chemical Industries Ltd Solid pharmaceutical preparation
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
CA2562391A1 (en) 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
JP2008511609A (ja) 2004-08-31 2008-04-17 ファイザー・プロダクツ・インク 低−溶解性薬物の速放及び徐放を組み合わせた制御放出型投薬形態
WO2007038115A2 (en) 2005-09-22 2007-04-05 Sb Pharmco Puerto Rico Inc. Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
ZA200805147B (en) 2005-12-22 2010-05-26 Takeda Pharmaceutical Solid preparation
WO2007114376A1 (ja) 2006-03-30 2007-10-11 Nippon Zoki Pharmaceutical Co., Ltd. 固形医薬製剤
JP2009534292A (ja) 2006-04-27 2009-09-24 武田薬品工業株式会社 塩酸ピオグリタゾンを有するアンジオテンシンｉｉ拮抗薬の医薬組成物
PL2120878T3 (pl) 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101269040A (zh) * 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸吡格列酮缓释滴丸及其制备方法
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2010039690A1 (en) 2008-09-30 2010-04-08 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
WO2011049309A2 (ko) 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
JP2011232302A (ja) 2010-04-30 2011-11-17 Ricoh Elemex Corp 画像検査方法及び画像検査装置
CN101884627B (zh) 2010-07-07 2012-01-25 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
AU2012326976B2 (en) 2011-10-21 2017-08-17 Takeda Pharmaceutical Company Limited Sustained-release preparation
KR20160056691A (ko) 2014-11-12 2016-05-20 삼성에스디아이 주식회사 이차전지

Also Published As

Publication number Publication date
TW201323018A (zh) 2013-06-16
AU2012326976A1 (en) 2014-05-29
NZ624275A (en) 2016-09-30
IN2014DN03169A (https=) 2015-05-22
SG2014012025A (en) 2014-06-27
EP2768487A1 (en) 2014-08-27
JP2014530802A (ja) 2014-11-20
UA113858C2 (uk) 2017-03-27
KR20140081826A (ko) 2014-07-01
CL2014000992A1 (es) 2014-09-05
CR20140213A (es) 2014-06-18
SG10201700121YA (en) 2017-03-30
UY34403A (es) 2013-05-31
ECSP14013328A (es) 2014-05-31
PE20141189A1 (es) 2014-09-24
US9907789B2 (en) 2018-03-06
AP2014007645A0 (en) 2014-05-31
ZA201403103B (en) 2015-08-26
MA35717B1 (fr) 2014-12-01
CA2852417A1 (en) 2013-04-25
MX2014004679A (es) 2014-08-01
WO2013058409A1 (en) 2013-04-25
AU2012326976B2 (en) 2017-08-17
DOP2014000077A (es) 2014-07-15
AU2012326976A2 (en) 2014-06-12
JP6093762B2 (ja) 2017-03-08
IL232114A0 (en) 2014-06-30
EA201490840A1 (ru) 2014-08-29
US20140248362A1 (en) 2014-09-04
CO6960544A2 (es) 2014-05-30
EP2768487B1 (en) 2020-06-03
AR088398A1 (es) 2014-05-28
CN104039313A (zh) 2014-09-10
TN2014000152A1 (en) 2015-09-30
PH12014500856A1 (en) 2014-05-19

Similar Documents

Publication Publication Date Title
BR112014004181A2 (pt) composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
EP2742155A4 (en) BIOMARKER FOR ALZHEIMER'S DISEASE AND / OR COGNITIVE LIGHT DISORDER, AND USE THEREOF
BR112013026341A2 (pt) composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
WO2013151666A3 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
HK1206601A1 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
BR112015011112A2 (pt) composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença.
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
WO2015001504A3 (en) Antibody formulations and methods
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112014008744A2 (pt) preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer
WO2013057570A3 (en) Acrylic polymer formulations
BR112013031712A2 (pt) composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença.
AP2014007804A0 (en) Compositions and methods for the treatment of hepatic diseases and disorders.
BR112013030554A2 (pt) forma cristalina de ciclosporina a, métodos de preparação e métodos para uso da mesma
HUE041883T2 (hu) Samidorphan (ALKS 33) és buprenorfin kombináció, depressziós zavarok kezelésére
BR112014009789A2 (pt) cisteamina no tratamento da doença fibrótica
EP3061455A4 (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
JP2013536184A5 (https=)
EP3086846A4 (en) Diagnosing and treating alzheimer's disease
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
CO7020857A2 (es) Procedimiento para la preparación de complejos de 68ga
HRP20260138T1 (hr) Postupak priprave 2,3,3,3-tetrafluoropropena
BR112015009088A2 (pt) formulações de levodopa para alívio rápido da doença de parkinson.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2536 DE 13-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.